That study was actually looking at Medicaid database and looking at how well patients are receiving antibiotic prophylaxis to prevent severe infections and sepsis and death from sickle cell disease and also receiving their TCD stroke screening, which we know is critical in preventing serious neurologic complications. This is one study that looked at patients in a more contemporary cohort...
That study was actually looking at Medicaid database and looking at how well patients are receiving antibiotic prophylaxis to prevent severe infections and sepsis and death from sickle cell disease and also receiving their TCD stroke screening, which we know is critical in preventing serious neurologic complications. This is one study that looked at patients in a more contemporary cohort. However, there have been multiple studies over multiple decades showing the same finding that an abysmally low number of patients are actually getting these very basic types of care. So we’re talking about prophylactic penicillin and ultrasound, and those things can be life-saving and also prevent life-changing events from happening.
So we really just wanted to highlight that while we’re excited about disease-modifying medications expanding and transformative and curative therapies expanding, we really aren’t even meeting the most basic needs of most of our patients in high-resource settings. And so I think those are the biggest challenges that are facing our patients. And so we need to first address those things before we can really think about how we’re going to be able to address those bigger challenges and providing those more complex treatments.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.